Popular on EntSun
- J French's #1 Album "I Don't Believe in Bad Days" Enters the Grammy Conversation - 159
- Wall Street's New Obsession? Tradewinds Aims to Revolutionize the $8B Gentlemen's Club Industry with National Peppermint Hippo™ Strategy $TRWD - 142
- Osric Langevin Unveils "Quantitative Trend" Framework for Multi-Asset Analysis in Q4 2025 - 139
- The OpenSSL Corporation and the OpenSSL Foundation Celebrate the Success of the Inaugural OpenSSL Conference in Prague - 136
- $73.6 Million in Order Backlog Poised for Explosive Growth in 2026; Streamlined Share Structure: Cycurion, Inc. (N A S D A Q: CYCU) $CYCU - 126
- Award-Winning Author Zane Carson Carruth Featured in USA Today for Inspiring Mission to Nurture Young Hearts Through Storytelling - 125
- An Officer and Gentlewoman, LLC Named Official Public Relations Agency for Upcoming Holiday Film "#WorstChristmasEver" - 124
- $430 Million 2026 Revenue Forecast; 26% Organic Growth; $500,000 Stock Dividend Highlight a Powerful AI & Digital Transformation Story: IQSTEL $IQST - 124
- Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform - 112
- 'Wild Hermit Wellness' Has Achieved Bestseller Status in Just 2 Months Since Launch Of Organic Skincare Line - 107
Similar on EntSun
- The global race for next-gen precious metals recovery is accelerating: $AABB is positioning itself with it's Revolutionary rGO Gold Recovery System
- NorthSky Celebrates One-Year Anniversary
- Operational Agility in High Demand: FOCUS Expands to Serve a Changing Insurance Market
- From November 24th to 27th, Fuqing Invites You to Join Us at BIG 5 to Jointly Build a New Future for Middle Eastern Architecture
- Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
- Stratum Nutrition's OVOLUX™ Named 2025 "Collagen Ingredient of the Year" by Beauty Innovation Awards
- Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
- New Smile Now Introduces RAYFace 3D Scanner to Advance Digital Surgery
- Ali Alijanian, DDS Featured in The Profitable Dentist Magazine
- CCHR: Study Finds Involuntary Commitment Fails to Prevent Suicide, Raises Risk
CPC Scientific Announces New California Peptide API Manufacturing Facility
EntSun News/10943036
SAN JOSE, Calif. - EntSun -- CPC Scientific Inc., a leading global peptide CRDMO (Contract Research, Development, and Manufacturing Organization) has invested in a new peptide API (Active Pharmaceutical Ingredient) manufacturing site, bringing many new jobs to Rocklin, California. The 41,000 sq ft facility located at 3880 Atherton Rd, Rocklin, CA 95765 will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity and will diversify CPC Scientific's supply chain.
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on EntSun News
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on EntSun News
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on EntSun News
- Aina More Drops "The Set" A Bold Coming Out Anthem Drenched in Sensuality, and Street Power
- The global race for next-gen precious metals recovery is accelerating: $AABB is positioning itself with it's Revolutionary rGO Gold Recovery System
- NorthSky Celebrates One-Year Anniversary
- Free At Last Bail Bonds Gives Back Through Major Holiday Food Distribution Efforts Across Metro Atlanta
- Formed From Soul: A Limited Clothing Collection Celebrating The Abundance Of The Soul
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on EntSun News
- Brightwater Lagoon brings winter wonderland to Southwest Florida with synthetic ice rink
- Discover Elevated Living - Preview the Stunning New Townhome Collection
- TownePlace Suites Prescott Valley, AZ Opens
- SIX7 Introduces Olfactory Neurodesign™ — The First Fragrance System Engineered to Influence Emotion, Memory, and Desire at the Neural Level
- GetKuwa emerging as GCC's #1 trusted online supplement marketplace as shoppers across UAE, Saudi Arabia, Kuwait, Qatar & Oman seek authenticity
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
Source: CPC Scientific Inc.
Filed Under: Technology
0 Comments
Latest on EntSun News
- From November 24th to 27th, Fuqing Invites You to Join Us at BIG 5 to Jointly Build a New Future for Middle Eastern Architecture
- Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
- Stratum Nutrition's OVOLUX™ Named 2025 "Collagen Ingredient of the Year" by Beauty Innovation Awards
- TV Stars Wanted for New THUNDERBALL Global show
- A Festive New Children's Story: Gallina the Talking Chicken Spreads Christmas Cheer
- New Documentary Exposes Deadly Link Between Psychiatric Drugs and Violence
- Sons of Liberty Museum Unveils "America at 250" Mobile Exhibit on Veterans Day 2025
- Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Bent Danholm Releases New Video Breaking Down the Rising Debate Over 50-Year Mortgages
- New Smile Now Introduces RAYFace 3D Scanner to Advance Digital Surgery
- Ali Alijanian, DDS Featured in The Profitable Dentist Magazine
- BeReal Wear Announces Early Black Friday Launch With Glow Up Bundle and Major 50% Off
- Trials And Tribulations Of Daytime's Most Popular Supercouples: Ranked
- Time After Time Stroud Launches UK-Exclusive Etsy Sale – 25% Off and Free Postage
- "Meet the Eatmons" Offer Financial Advice ahead of the Holidays
- CCHR: Study Finds Involuntary Commitment Fails to Prevent Suicide, Raises Risk
- Slotozilla's Q3 2025: SBC Lisbon Outcomes and Partnership Expansion
- Historic Announcement for the Global Car Rental Industry
- Swiss Star and Wellness Founder Michèle Tambika Cast in Lead Role for New Bicoastal Series, Loft Life: High-Rise Hijinks
- Impro's Dickens Unscripted at North Coast Repertory Theatre
